Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

Immediately postoperatively, corneal graft displacement and peripheral corneal edema which remained stable during the first postoperative month were evident on slit lamp examination. Three months ...

35, No.9), we published an article, “What's Your Diagnosis? Exophthalmos and corneal edema in a young ferret,” in which we diagnosed an 8-week-old ferret with glaucoma in its right eye.

These supports will aid Aurion's development of AURN001, a treatment for corneal edema, or swelling of the cornea, which can occur as a secondary effect of corneal endothelial disease. Aurion ...

a novel cell therapy for the treatment of corneal edema secondary to corneal endothelial disease. AURN001 is a combination cell therapy product candidate comprised of allogeneic human corneal ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...